CRF Inc. e-Diary Technology Use Tops 100,000 Patients Worldwide


Applied Clinical Trials

Company continues to set experience records for the electronic patient reported outcomes industry

Waltham, MA - June 15, 2005 - CRF Inc., the world leader in electronic Patient Reported Outcomes (e-PRO) and wireless data collection solutions for the biopharmaceutical industry, today announced that its mobile technology has connected more than 100,000 patients across 58 countries and in 48 languages. This milestone sets a new industry experience standard and continues CRF Inc.'s history of establishing industry records, which began when the company became the first e-PRO provider to reach 50,000 patients in February 2004.

"While this patient milestone is a significant accomplishment, this is just the beginning for our company, our partners, and the e-PRO industry," said Pamela McNamara, Chief Executive Officer of CRF Inc. "Our electronic patient diaries are the most widely used in the world and we are working with our clients to execute increasingly complex clinical studies. The results we have delivered to date are the true indicator of CRF Inc.'s experience and expertise. We have realized 95 percent compliance rates across all major therapeutic areas and patient populations -- from the young and active to the elderly and terminally ill."

In addition to the 100,000 patient milestone, 2005 has been a very exciting year for CRF Inc. The company has signed a number of new customers, secured additional funding, strengthened its management team, and attained further industry recognition. Some recent company highlights include:

- New Clients: CRF Inc. has signed a number of new clients in the first half of 2005, including Allergan and Schering AG. Thirty-eight pharmaceutical and biotechnology companies have used CRF Inc. technologies, including 16 of the world's 20 largest pharmaceutical companies.

- New Technology Development Funding: CRF Inc. secured $1.3 million (EUR 1.0 million) from The National Technology Agency of Finland (Tekes). Initial funding from Tekes in 2003 enabled the company to develop its award-winning e-PRO technology, TrialMax, and establish a technology advantage over its competition. This new round of funding will be used to continue research and development TrialMax and assist CRF Inc. in its efforts to expand the application of e-PRO technology in healthcare.

- New Staff: CRF Inc. strengthened management of its customer delivery, clinical operations, and business development teams through a number of new hires in 2005. Susan MacIntyre joined CRF Inc. as Clinical Operations Director, USA, Ted Olsson was appointed VP of Customer Delivery, Greg Cohee joined the company as Director of Business Development, and Kurt Mussina was named VP of Commercial Operations.

- Industry Recognition: CRF Inc. was a recipient of the Red Herring 100 Europe, a selection of the 100 private companies in Europe and Israel that play a leading role in innovation and technology.

About CRF Inc.
CRF Inc. is the leading global provider of electronic Patient Reported Outcomes (e-PRO) and wireless data collection solutions for the biopharmaceutical industry. Through innovative technology and a thorough understanding of drug development and mobile computing, the company is driving the change to safer and more efficient paper-free clinical trials. CRF Inc.'s technology has been used by more than 100,000 patients across 58 countries in 48 languages for 32 indications. The company has demonstrated the industry's highest patient compliance rates - an average 95 percent compliance through Phase I, II, III and IV clinical trials - and unmatched patient and research site acceptance.

CRF Inc.'s award-winning product, TrialMax, is a flexible and customizable e-PRO technology that provides real-time patient monitoring, outstanding data accuracy and increased safety. Its unique features enable clinical trial sponsors to collect more valuable data faster and conduct complex clinical trials with greater flexibility than other e-PRO solutions. CRF Inc.'s experience combined with its dedication to ensuring the highest quality and most responsive customer service has made the company the biopharmaceutical industry's most trusted partner.

For more information, please visit

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.